Reporting that there were 68,000 completed Cologuard non-invasive DNA tests for colon cancer over the last quarter, Exact Sciences improved on its net loss year over year.
For the quarter ending Sept. 30, the Madison company posted a net loss of $37.8 million (36 cents/share) on revenues of $28.1 million.
Last year, the net loss was $42.9 million (45 cents/share) on $12.6 million in revenue.
